Pricing Zolgensma – the world's most expensive drug.

Therefore, the cost of capital for current R&D projects may not reflect the cost of capital for a new high risk-profile research area, like gene therapy and, therefore, the investor may add a premium to the cost of capital based on his judgment. The price of Zolgensma is about ten times higher than that of Spinraza, and this big difference can be explained by the fact that it is administered only once, whereas Spinraza is an annual treatment with continuous revenues for the remainder of each patient's life. This consistency between prices of Zolgensma and Spinraza validates the concept of the described Pricing Model, but it should also be noted that it is based on long-term maintained treatment effect of Zolgensma following a single administration. Keywords: Price valuation reimbursement; orphan disease EN Price valuation reimbursement orphan disease 1 3 3 11/07/22 20221201 NES 221201 A heated discussion has recently broken out in Europe about the price of Zolgensma, "the most expensive drug ever". [Extracted from the article]